rs587782074
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM2PP3_StrongPP5_Very_Strong
The NM_001406875.1(PMS2):c.-651G>T variant causes a 5 prime UTR premature start codon gain change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000124 in 1,612,548 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_001406875.1 5_prime_UTR_premature_start_codon_gain
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 14 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.00000657 AC: 1AN: 152232Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000160 AC: 4AN: 250350Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135606
GnomAD4 exome AF: 6.85e-7 AC: 1AN: 1460316Hom.: 0 Cov.: 32 AF XY: 0.00000138 AC XY: 1AN XY: 726480
GnomAD4 genome AF: 0.00000657 AC: 1AN: 152232Hom.: 0 Cov.: 32 AF XY: 0.0000134 AC XY: 1AN XY: 74376
ClinVar
Submissions by phenotype
Lynch syndrome Pathogenic:2
The c.23+1G>T variant in the PMS2 gene is located at the canonical splice site of intron 1 and is predicted to inflict donor loss (SpliceAI delta score: 0.99), resulting in alternative splicing and disrupted protein product. The variant has been reported in an individual with paraganglioma (PMID: 29625052). Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 28514183, 25512458, 35223509). The variant is reported in ClinVar (ID: 141871). Variants affecting the same donor splice site including c.23+1G>C, c.23+1G>A, c.23+2T>G, c.23+2T>A have also been reported as likely pathogenic in ClinVar (ClinVar ID: 821062, 1195870, 1517684, 1789279). This variant is rare in the general population according to gnomAD (4/250350 chromosomes). Therefore, the c.23+1G>T variant in the PMS2 gene has been classified as likely pathogenic. -
The c.23+1G>T variant in the PMS2 gene is located at the canonical splice site of intron 1 and is predicted to inflict donor loss (SpliceAI delta score: 0.99), resulting in alternative splicing and disrupted protein product. The variant has been reported in an individual with paraganglioma (PMID: 29625052). Loss-of-function variants in PMS2 are known to be pathogenic (PMID: 28514183, 25512458, 35223509). The variant is reported in ClinVar (ID: 141871). Variants affecting the same donor splice site including c.23+1G>C, c.23+1G>A, c.23+2T>G, c.23+2T>A have also been reported as likely pathogenic in ClinVar (ClinVar ID: 821062, 1195870, 1517684, 1789279). This variant is rare in the general population according to gnomAD (4/250350 chromosomes). Therefore, the c.23+1G>T variant in the PMS2 gene has been classified as likely pathogenic. -
Lynch syndrome 4 Pathogenic:2
- -
This variant is considered likely pathogenic. This variant occurs within a consensus splice junction and is predicted to result in abnormal mRNA splicing of either an out-of-frame exon or an in-frame exon necessary for protein stability and/or normal function. -
not provided Pathogenic:1
This variant is denoted PMS2 c.23+1G>T or IVS1+1G>T and consists of a G>T nucleotide substitution at the +1 position of intron 1 of the PMS2 gene. This variant destroys a canonical splice donor site and is predicted to cause abnormal gene splicing, leading to either an abnormal message that is subject to nonsense-mediated mRNA decay or to an abnormal protein product. This variant was observed in at least one individual referred for hereditary cancer testing (LaDuca 2017). Based on the current evidence, we consider this variant to be pathogenic. -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change affects a donor splice site in intron 1 of the PMS2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in PMS2 are known to be pathogenic (PMID: 21376568, 24362816). This variant is present in population databases (rs587782074, gnomAD 0.02%). Disruption of this splice site has been observed in individual(s) with clinical features of Lynch syndrome and/or paraganglioma (PMID: 29625052, 36451132; internal data). ClinVar contains an entry for this variant (Variation ID: 141871). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Lynch syndrome 4;C5436817:Mismatch repair cancer syndrome 4 Pathogenic:1
- -
Hereditary cancer-predisposing syndrome Pathogenic:1
The c.23+1G>T intronic variant results from a G to T substitution one nucleotide after coding exon 1 of the PMS2 gene. In silico splice site analysis predicts that this alteration will weaken the native splice donor site and may result in the creation or strengthening of a novel splice donor site. The stop codon in the predicted resulting transcript occurs in the 5' end ofthe PMS2 gene. As such, this alteration may escape nonsense-mediated mRNAdecay and/or be prone to rescue by reinitiation (Rivas et al. Science. 2015 May 8;348(6235):666-9; Lindeboom et al. Nat Genet. 2016 Oct;48(10):1112-8; Rhee et al. Sci Rep. 2017 May 10;7(1):1653). The exact functional effect of this alteration is unknown; however, the impacted region is critical for protein function (Ambry internal data). This nucleotide position is highly conserved in available vertebrate species. As such, this alteration is classified as likely pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at